Pentasa Slow Release Tablets contain the active ingredient mesalazine (also known as mesalamine). Mesalazine belongs to a class of medications called aminosalicylates, which are used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn?s disease.
The exact mechanism of action of mesalazine in treating IBD is not fully understood, but it is believed to involve the inhibition of inflammatory mediators and the restoration of the intestinal lining?s barrier function.
It?s important to take Pentasa Slow Release Tablets exactly as prescribed by a healthcare professional, typically with food to minimize gastrointestinal side effects. Dosage and duration of treatment will vary depending on the severity of the condition and individual patient response. It?s also crucial to report any side effects or concerns to your healthcare provider while using Pentasa.